NeuroEM Therapeutics Private Investor Briefing – Virtual

Event Details

NeuroEM Therapeutics Private Investor Briefing - Virtual

by CONNECTpreneur Investor Network

THURSDAY, April 2, 2026

Please note that this meeting is for DIRECT and ACTIVE investors only. All RSVPs must be pre-registered on this Eventbrite site with the investor criteria filled out. All RSVPs are subject to review and approval.

Opus8 is hosting a virtual, invitation-only private investor briefing featuring NeuroEM, a medical technology company developing a non-invasive treatment designed to slow and potentially reverse the effects of Alzheimer’s disease.

NeuroEM’s patented TEMT-RF (Transcranial Electro-Magnetic Treatment using Radio Frequencies) platform targets the underlying biological drivers of Alzheimer’s by reducing toxic protein buildup, decreasing inflammation, and restoring cellular energy in the brain. The company’s device has received FDA Breakthrough Device designation, positioning it at the forefront of next-generation neurological therapeutics.

Company Overview

NeuroEM is advancing a clinically validated, non-pharmaceutical treatment approach for Alzheimer’s disease—one of the largest and fastest-growing healthcare challenges globally. Built on more than a decade of university research and supported by NIH funding, NeuroEM’s technology has demonstrated measurable cognitive improvement in early clinical trials and is designed to deliver scalable, at-home treatment for millions of patients.

What Differentiates NeuroEM

• Breakthrough Clinical Results — In early clinical trials, 7 of 8 Alzheimer’s patients showed measurable cognitive improvement within two months of treatment
• Strong Scientific Foundation — 10+ years of university research, supported by two NIH grants and extensive peer-reviewed validation
• Robust Intellectual Property — 9 issued patents with 10 additional patents pending worldwide
• Massive Market Opportunity — Alzheimer’s affects 55M+ patients globally, representing a healthcare market exceeding $300B annually
• Capital Efficient Growth — Currently raising a $5M Seed Preferred round at a $15M pre-money valuation, with a planned $5–10M Series A

Event Details

Date: April 2, 2026

Time: 11:30 AM – 12:30 PM EDT

Location: Online via Zoom

Attendance is limited and curated.

Important Notes

Please note that this meeting is for DIRECT and ACTIVE investors only. All RSVPs must be pre-registered on this Eventbrite site with the investor criteria filled out. All RSVPs are subject to review and approval.

To request investor materials, contact:
Avery North — anorth@opus8.com

Event Details